MediciNova stock up 85% in September as pivotal ALS trial reaches final patient visit
MediciNova has completed the final patient visit in the blinded portion of its 234-patient COMBAT-ALS study, starting the countdown to pivotal MN-166 results expected by year-end as MNOV shares emerge as one of September’s strongest-performing healthcare stocks.
